Rankings
▼
Calendar
RXRX (Recursion Pharmaceuticals, Inc.) Stock Financials & Earnings | Market Cap Arena
RXRX
Recursion Pharmaceuticals, Inc.
Mkt Cap
$2B
Healthcare
·
Biotechnology
·
🇺🇸 United States
·
NASDAQ
Revenue (TTM)
$75M
Net Income (TTM)
-$645M
EPS (TTM)
-$1.48
Free Cash Flow (TTM)
-$378M
Gross Margin
-32.1%
Op. Margin
-869.3%
Net Margin
-864.7%
FCF Margin
-507.3%
P/S Ratio (TTM)
21.1x
P/E Ratio (TTM)
—
YoY Rev Growth
+27.5%
Employees
—
Earnings Reports
▶
Q4 2025
NEW
Browse All Reports
Quarterly
FY
Revenue & Profitability
Revenue
Gross Profit
Operating Income
Quarter
Revenue
Gross Profit
Op. Income
Q1 23
$12M
-$314K
-$70M
Q2 23
$11M
$2M
-$82M
Q3 23
$10M
-$775K
-$100M
Q4 23
$11M
$743K
-$99M
Q1 24
$13M
$2M
-$96M
Q2 24
$14M
$5M
-$101M
Q3 24
$26M
$14M
-$98M
Q4 24
$5M
-$8M
-$184M
Q1 25
$15M
-$7M
-$191M
Q2 25
$19M
-$1M
-$176M
Q3 25
$5M
-$24M
-$172M
Q4 25
$36M
$9M
-$108M
marketcaparena.com
Valuation
P/S Ratio
P/E Ratio
Quarter
P/S
P/E
Q1 23
33.8x
—
Q2 23
31.6x
—
Q3 23
33.5x
—
Q4 23
35.9x
—
Q1 24
34.8x
—
Q2 24
32.4x
—
Q3 24
24.4x
—
Q4 24
26.9x
—
Q1 25
26.3x
—
Q2 25
24.4x
—
Q3 25
36.2x
—
Q4 25
21.1x
—
marketcaparena.com
Operating Cash Flow
Operating Cash Flow
Free Cash Flow
Quarter
Operating CF
Free CF
Q1 23
-$73M
-$79M
Q2 23
-$67M
-$71M
Q3 23
-$73M
-$74M
Q4 23
-$74M
-$76M
Q1 24
-$102M
-$109M
Q2 24
-$82M
-$86M
Q3 24
-$59M
-$64M
Q4 24
-$115M
-$117M
Q1 25
-$132M
-$134M
Q2 25
-$76M
-$80M
Q3 25
-$117M
-$118M
Q4 25
-$46M
-$47M
marketcaparena.com
Capital Expenditures
CapEx
Quarter
CapEx
Q1 23
$5M
Q2 23
$4M
Q3 23
$827K
Q4 23
$2M
Q1 24
$7M
Q2 24
$4M
Q3 24
$5M
Q4 24
$2M
Q1 25
$2M
Q2 25
$3M
Q3 25
$243K
Q4 25
$1M
marketcaparena.com
OpEx vs Revenue Growth (YoY)
Revenue Growth
OpEx Growth
Quarter
Revenue Growth
OpEx Growth
Q1 23
+129.0%
+33.8%
Q2 23
+43.9%
+25.6%
Q3 23
-22.6%
+45.0%
Q4 23
-22.3%
+46.7%
Q1 24
+11.2%
+33.9%
Q2 24
+30.8%
+24.0%
Q3 24
+158.2%
+13.5%
Q4 24
-57.5%
+71.9%
Q1 25
+9.3%
+87.7%
Q2 25
+32.6%
+69.9%
Q3 25
-80.2%
+42.5%
Q4 25
+687.8%
-23.6%
marketcaparena.com
Stock-Based Compensation
SBC ($)
% of Revenue
Quarter
SBC ($)
% of Revenue
Q1 23
$9M
72.6%
Q2 23
$12M
107.2%
Q3 23
$17M
166.2%
Q4 23
$16M
151.4%
Q1 24
$16M
119.5%
Q2 24
$17M
114.7%
Q3 24
$18M
70.0%
Q4 24
$31M
682.4%
Q1 25
$36M
244.5%
Q2 25
$26M
136.9%
Q3 25
$25M
487.8%
Q4 25
$0
0.0%
marketcaparena.com
OpEx Breakdown
R&D
G&A
Quarter
R&D
G&A
Q1 23
$47M
$23M
Q2 23
$55M
$28M
Q3 23
$70M
$29M
Q4 23
$69M
$30M
Q1 24
$68M
$31M
Q2 24
$74M
$32M
Q3 24
$75M
$38M
Q4 24
$98M
$77M
Q1 25
$130M
$55M
Q2 25
$129M
$47M
Q3 25
$121M
$42M
Q4 25
$83M
$34M
marketcaparena.com
Revenue Segments
License and Service
Grant
Quarter
License and Service
Grant
Q1 23
$12M
—
Q2 23
$11M
$1K
Q3 23
$10M
$431K
Q4 23
$11M
$267K
Q1 24
$13M
$303K
Q2 24
$14M
$13K
Q3 24
$26M
—
Q1 25
$15M
—
Q2 25
$19M
$120K
Q3 25
$5M
$192K
Q4 25
$35M
$186K
marketcaparena.com
War Chest
Cash & Equivalents
Short-Term Investments
Quarter
Cash
Short-term Investments
Total
Q1 23
$473M
$0
$473M
Q2 23
$406M
$0
$406M
Q3 23
$387M
$0
$387M
Q4 23
$392M
$0
$392M
Q1 24
$300M
$0
$300M
Q2 24
$474M
$0
$474M
Q3 24
$428M
$0
$428M
Q4 24
$594M
$0
$594M
Q1 25
$500M
$0
$500M
Q2 25
$528M
$0
$528M
Q3 25
$660M
$0
$660M
Q4 25
$743M
$0
$743M
marketcaparena.com
Shares Outstanding
Shares Outstanding
Quarter
Shares (Diluted)
QoQ Change
Q1 23
192M
+3.2%
Q2 23
201M
+5.1%
Q3 23
214M
+6.4%
Q4 23
233M
+8.8%
Q1 24
236M
+1.2%
Q2 24
242M
+2.6%
Q3 24
283M
+16.7%
Q4 24
336M
+18.9%
Q1 25
403M
+19.9%
Q2 25
417M
+3.6%
Q3 25
447M
+7.1%
Q4 25
527M
+17.8%
marketcaparena.com
Revenue Per Employee
Revenue / Employee
Year
Revenue/Employee
Employees
FY 19
—
—
FY 20
—
—
FY 21
$25K
400
FY 22
$79K
500
FY 23
$88K
500
FY 24
$74K
800
FY 25
$373
200K
marketcaparena.com